Profile of a Community Pharmacist

The ADAM Study has 50 Lloyds Pharmacies working as trial pharmacies across the country.  The pharmacists and their teams support the study by dispensing acamprosate in our trial bottles with MEMS Caps attached, and by keeping a record of the prescription each participant has, throughout their time on the Juliana Musa_Community Pharmaciststudy.  They are a vital part of the trial phase, seeing our participants on a monthly basis and therefore acting as a key point of contact.  All pharmacists and many of their team members have attended several training sessions so far to keep them up to date on the study procedures and requirements.

Juliana Musa is a pharmacist working at the Kimberworth Pharmacy in Rotherham, and she kindly agreed to a telephone interview with one of our researchers to help us understand how to become a pharmacist, and what the role entails.

Name: Juliana Musa               
Pharmacy: Kimberworth, Rotherham


Why did you decide to become a pharmacist?

My passion to become a pharmacist was driven by the desire to help patients and people. I have always been interested in pharmacy because, it is different from medicine which most people study back home. Understanding the various medications and how they would benefit patients is important; as I am motivated towards helping patients, and making their lives better.


Why a community pharmacist not industry or hospital?   

As a community pharmacist, you are in contact with the patient and this generates a certain closeness with them, thus producing positive results. With this close relationship established with the patient, they rely on you for medication or advice, which doesn’t happen in the same way in hospitals or the other arms of pharmacy.  It is all about being patient-centred for me.


What is your background, and how did you train to become a pharmacist?

I studied pharmacy in Nigeria, and graduated in 2000.  After practising as a community pharmacist in Nigeria, I came to the UK in 2007 and decided to take the conversion courses I needed to practise here.  I attended Robert Gordon University in Aberdeen, studying a one year programme with the final year pharmacy students, on completion; I did a pre-registration placement and exams which enable me to practise in the UK.  It has been an amazing transition for me, and a really good experience.


How long have you practised as a pharmacist?  Was that in community or hospital elsewhere?

I’ve been practising as a pharmacist for about 17 years.


How long have you worked for Lloyds?

This is my 6th year of working for Lloyds.


How long have you worked at the Kimberworth branch in Rotherham?

I’ve worked at the Kimberworth branch for 5 years. I did one year in a different Lloyds branch and before that and a few months at other branches, until I decided to come here. I’ve mainly worked for Lloyds but I have done a few hours working in other community pharmacies, to see their work pattern.


What is the best part of your job, and why?

The clinical aspect is the best part for me, as patients come in to enquire about particular medications and I have positive answers for them.  Also, when they come in for consultation about some kind of illness or ailment, and the medication I have recommended works for them and they come back to say “thank you pharmacist, this worked “.  Having consultations with patients is where I find my joy in practise so far.


What is the most challenging part of your job, and why?

For me the challenging bit is we do encounter language barriers from time to time. However facilities have been put in place by the company to assist this. We have also built good relationships with the community who help us with this


How have you found being involved in the ADAM study and the training you received?

I’m enthusiastic of the study and I’m definitely interested. I’m just working with the information you’ve provided us.  It is what helps us to get new services into the business, and if it is a trial that will benefit patients and the business, then, I am certainly open to it.  I am personally interested to see practical results.


What else could pharmacists and the pharmacy team do to support patients and families who are experiencing problems with alcohol now?

I believe counselling will go a long way towards addressing this problem. You need the family members to be present as well and to identify the root cause of the problem, duration of this patient current condition. Communication with patient is vital, as you can learn more, understanding patients to what may have triggered illness, so I feel we should talk and treat patients with respect.



How do you see the role of community pharmacists in the future, with regards to working with patients who may be experiencing problems with alcohol?     

Community pharmacists have a crucial role in the future as it will change and become more focused on patients; where pharmacists can become prescribing pharmacists, which has already started in some areas.  As a prescribing pharmacist, you can specialise in specific disease conditions or ailments.  Thus, you could have someone who specialises in alcohol treatment and runs clinics. I think it is the way forward for pharmacies, which is really good, because you are freeing up doctor’s time, and you have that good rapport with the patient and you can solve the problems immediately without needing the GP.


Do they have any research experience? Would you be interested to do more research in future, what sort of research and why?

I’ve never been fascinated by academics or research although if it is patient centred I am open to it.  I will welcome such an opportunity as long as it is patient centred.




Top 10 priorities for alcohol-related liver disease identified

dame-sally-davies“The number of people with alcohol related liver disease has been increasing over the last few decades: death rates have risen considerably in this time and alcohol is now one of the most common causes of death in the UK. So this is an important area for research. It’s vital that we bring together patients, carers and clinicians to decide jointly what the priorities for research are in this area, and the NIHR is pleased to support the James Lind Alliance in doing so.”

Professor Dame Sally C. Davies FRS FMedSci
Chief Medical Officer and Chief Scientific Adviser at the Department of Health

For the past two and a half years, I have been a steering group member for the first ever James Lind Alliance (JLA), Alcohol-Related Liver Disease Priority Setting Partnership – to identify priorities for research. Our group comprises of a diverse range of patients, carers, clinicians and researchers. I was involved in highlighting community pharmacy practice and research perspectives, to the group, based on my clinical and research experience. Recently we held a workshop in London, where the top 10 priorities for alcohol-related liver disease were identified. Below is a press release outlining our work and the top 10 priorities.

Dr Ranjita Dhital PhD, MRPharmS, Post-Doctoral Research Pharmacist for the ADAM study, IoPPN, King’s College London. Email:

PRESS RELEASE                                                     

NIHR and BSG launch top 10 research priorities for alcohol-related liver disease

‘What are the most effective ways to help people with alcohol-related liver disease stop drinking?’ is the top priority question for alcohol-related liver disease research, according to new results from the JLA’s Alcohol-Related Liver Disease Priority Setting Partnership (PSP).

Research into alcohol-related liver disease has been highlighted as a priority by the NIHR, which jointly funded the James Lind Alliance (JLA) PSP with the British Society of Gastroenterology (BSG). Alcohol-related liver disease has become the most common type of alcohol-related death in England. It accounted for 64% (4,441) of all alcohol-related deaths in 2011, and for 65% and 62% of male and female alcohol-related deaths respectively – most among those aged 50-59 years.

Simon Denegri, NIHR National Director for Patients and the Public in Research, said:
“The more we understand the priorities and concerns of people with alcohol-related liver disease, their carers and those health professionals treating them, the more we can ensure that the research that is funded is relevant to their needs. So I am delighted to see the results of the NIHR and BSG PSP have launched today. I hope it will be the basis for future research collaborations between patients, carers, health professionals and researchers leading to new ways to care for and treat people with this terrible disease.”

The PSP was set up through the JLA last year (2015). Data were collected through a survey asking patients, carers and health professionals for their unanswered questions around the diagnosis, treatment and care of alcohol-related liver disease. Over 230 responses were received from across the UK, and the top 25 questions were then taken to the JLA Alcohol-Related Liver Disease PSP workshop in September (2016), where health professionals, patients and carers worked collaboratively to reach the following final Top 10:

  1. What are the most effective ways to help people with alcohol-related liver disease stop drinking?
  2. What are the most effective ways of delivering healthcare education and information about excessive alcohol consumption, the warning signs and the risks of alcohol-related liver disease to different demographics (including young people)?
  3. What is the most effective model of community-based care for patients with alcohol-related liver disease?
  4. What is the patient’s experience of alcohol-related liver disease?
  5. Do attitudes to perceived ‘self-induced illness’ amongst healthcare professionals affect treatment, care provision and compassion for individuals with alcohol-related liver disease?
  6. What are the most effective strategies to reduce the risk of alcohol-related liver disease in heavy drinkers?
  7. Does the stigma associated with alcohol misuse affect the willingness of people with alcohol-related liver disease to ask for help?
  8. What interventions improve survival in individuals with complications of advanced alcohol-related cirrhosis?
  9. How should depression be managed in the context of alcohol-related liver disease?
  10. What models of involvement of palliative care services in advanced alcohol-related liver disease are most beneficial?

The full list of verified unanswered questions, is available on the alcohol-related liver disease PSP website:

Dr Steve Ryder, Chair of the British Society of Gastroenterology (BSG) /British Association for the Study of the Liver (BASL) Research Development Group, said:
“Alcohol-related liver disease (ARLD) is a disorder that has had disproportionately little research attention or spending in the past, despite its impact on patients and their families. ARLD remains the second highest cause of years of life lost in young men.  It is a huge step forward that the NIHR with BSG have been able to help set a series of key research questions which cover all aspects of ARLD, from its stigma to the potential areas for new treatments.  BSG believes that this provides a key step in ensuring that people and carers of people with ARLD will gain access to better understanding of the disorder and better treatments in the near future. We look forward to calls for research to answer these questions.”

Dawn Pallant, a patient involved in the Alcohol-related liver disease PSP workshop, said: “It was a real privilege to be involved in this day organised by the JLA. It is extremely unusual and an extraordinary opportunity for all of these people (patients, doctors, medical specialists, carers, charities and potential funding bodies) to have the time to meet with the prime objective of setting priorities to fund research. “

The Top 10 priorities encourage new research into alcohol-related liver disease and guide researchers to answer the questions that are important to those affected by the disease. To find out more about the work of this JLA PSP, please visit

For more information please contact:
Kelly Lockhart – Communications
National Institute for Health Research Evaluation, Trials and Studies Coordinating Centre
Tel: 023 80595775 Email:

Notes to editors
JLA: The James Lind Alliance Priority Setting Partnership (JLA PSP) infrastructure is hosted by the National Institute for Health Research (NIHR) to provide the support and processes for Priority Setting Partnerships (PSPs). PSPs aim to help patients, carers and clinicians work together to agree which are the most important treatment uncertainties affecting their particular interest, in order to influence the prioritisation of future research in that area. For further information, visit the JLA website (

NIHR: The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible benefits for patients and the economy, and developed and supported the people who conduct and contribute to applied health research. The NIHR plays a key role in the Government’s strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. Together, the NIHR people, programmes, centres of excellence and systems represent the most integrated health research system in the world. For further information, visit the NIHR website (

BSG: The British Society of Gastroenterology (BSG; is a registered charity and the professional organisation for the promotion of gastroenterology and hepatology within the United Kingdom. We have over 3,000 members, drawn from the ranks of physicians, surgeons, pathologists, radiologists, scientists, nurses, dietitians, and others interested in the field. Founded in 1937, the BSG has grown from a club to a major force in British medicine and a renowned name at European and broader international levels.